Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 535

Results For "CE"

9352 News Found

Amcor's Bloom Biorenewables secures $14 million Series A Funding
Packaging | April 03, 2025

Amcor's Bloom Biorenewables secures $14 million Series A Funding

Bloom has pioneered a technology to transform plant waste into valuable chemical products


SK Capital invests in Spectrum Vascular
News | April 02, 2025

SK Capital invests in Spectrum Vascular

Founded in 2023, Spectrum Vascular acquired the vascular access businesses of Cook Medical in 2023 and AngioDynamics in 2024


Coveris launches circular solution for stretch sleeves with ReCover
Packaging | April 02, 2025

Coveris launches circular solution for stretch sleeves with ReCover

The introduction of Coveris’ sleeve-to-sleeve PCR model complements sectors such as bottling where an established recycling infrastructure exists


Morepen secures Loratadine approval for export to China
Drug Approval | April 01, 2025

Morepen secures Loratadine approval for export to China

This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets


Briefs: AstraZeneca Pharma India, Pharmaids and Dr. Agarwal's Health Care
News | April 01, 2025

Briefs: AstraZeneca Pharma India, Pharmaids and Dr. Agarwal's Health Care

AstraZeneca Pharma India discontinues manufacturing of Imdur


Akums launches Ripasudil + Timolol combination for glaucoma treatment
News | April 01, 2025

Akums launches Ripasudil + Timolol combination for glaucoma treatment

The new combination therapy offers a dual mechanism of action for superior intraocular pressure control


Lonza implements streamlined operating model
News | April 01, 2025

Lonza implements streamlined operating model

Lonza’s new simplified and streamlined operating model is designed to support its One Lonza vision and strategy


Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug
News | March 29, 2025

Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug

Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851


Merck seeks FDA approval for subcutaneous pembrolizumab
Drug Approval | March 29, 2025

Merck seeks FDA approval for subcutaneous pembrolizumab

Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy